AACR 2022 | 177Lu-PSMA I&T for patients with PSMA-positive mCRPC

Scott T. Tagawa, MD, MS, FACP, Weill Cornell Medical College, New York, NY, discusses the potential benefits of 177Lu-PSMA I&T for early and late-line prostate-specific membrane antigen (PSMA) positive metastatic castration resistant prostate cancer (mCRPC). The option of an effective PSMA-targeted therapy is could provide a significant benefit for this cohort, with 90% of prostate cancers being PSMA positive and tumors in this cohort being generally amenable to radiotherapy. The observed benefits in later stage multi-resistant patients, such as increased overall survival, increased morale, and lower toxicity, are on average short-lived but nonetheless valuable in this difficult-to-treat population. Research is now looking towards this treatment in mCRPC chemotherapy-naïve settings where less resistance and lower hazard ratios are expected. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.